-+ 0.00%
-+ 0.00%
-+ 0.00%

Inspira Technologies OXY Deploys, Initiates Structured Commercial Evaluation Of Its FDA-Cleared INSPIRA ART100 System

Benzinga·02/18/2026 13:39:54
Listen to the news

Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) ("Inspira  Technologies" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced the deployment and initiation of a structured commercial evaluation of its U.S. Food and Drug Administration ("FDA")-cleared INSPIRA™ ART100 system (the "ART100") at a new and additional leading U.S. academic medical center.

The partnering institution is a prominent health system serving a large patient population, and is ranked among New York State's top 10 hospitals in Newsweek's World's Best Hospitals 2025 ranking.

This deployment expands Inspira Technologies' presence within the Tier-1 U.S. hospital market. The ART100 system has been integrated into the center's clinical workflow to support a structured evaluation designed to define clinical protocols and potential broader institutional adoption. This activity builds upon the Company's FDA clearance and ongoing commercial activity at other leading U.S. healthcare facilities.